Results of phase III PRIMO-CABG trial presented.

2003 DEC 8 - (NewsRx.com & NewsRx.net) -- Alexion Pharmaceuticals, Inc., (ALXN) announced that Edward D. Verrier, MD, William K. Edmark professor and chief of cardiothoracic surgery at the University of Washington, presented the phase III trial results of the investigational drug pexelizumab in patients undergoing coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass - "Pexelizumab for Reduction in Infarction and Mortality in Coronary Artery Bypass Graft Surgery," or PRIMO-CABG.

The results were presented at the Late Breaking Clinical Trials Session of the American Heart Association Scientific Sessions in Orlando, Florida. Alexion conducted the PRIMO-CABG trial together with Procter & Gamble Pharmaceuticals, and initially described top-line observations of the trial on August 4, 2003.

The total Intent-to-Treat population (n=3,099) consisted of patients undergoing CABG-alone …